VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 39 filers reported holding VERONA PHARMA PLC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $486,930 | -32.3% | 29,873 | -12.2% | 0.22% | -31.6% |
| Q2 2023 | $719,331 | -24.9% | 34,027 | -28.7% | 0.33% | -57.9% |
| Q1 2023 | $958,278 | -46.6% | 47,723 | -30.5% | 0.78% | -26.7% |
| Q4 2022 | $1,794,896 | +486.6% | 68,691 | +87.5% | 1.07% | +369.6% |
| Q1 2021 | $306,000 | +63.6% | 36,638 | +37.3% | 0.23% | +90.8% |
| Q4 2020 | $187,000 | – | 26,681 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 4,249,918 | $69,273,663 | 7.59% |
| Aisling Capital Management LP | 1,115,352 | $18,180,238 | 7.49% |
| NEA Management Company, LLC | 5,108,563 | $91,031,474 | 7.03% |
| Octagon Capital Advisors LP | 2,369,000 | $38,614,700 | 5.93% |
| Knoll Capital Management, LLC | 200,000 | $3,260,000 | 3.38% |
| Frazier Life Sciences Management, L.P. | 3,014,349 | $49,133,889 | 3.26% |
| Perceptive Advisors | 4,007,197 | $65,317,311 | 2.18% |
| RA Capital Management | 6,317,990 | $102,983,237 | 2.03% |
| Deep Track Capital, LP | 3,187,415 | $51,954,865 | 2.00% |
| Carlyle Group Inc. | 2,457,500 | $40,008,100 | 1.74% |